Sandoz and Vyvanse Generics
Sandoz has launched a generic version of lisdexamfetamine dimesylate, the active ingredient in Shire's (now Takeda's) ADHD medication Vyvanse [1]. This generic formulation is available in capsule form [1].
When Did the Vyvanse Patent Expire?
The patent for Vyvanse has faced multiple challenges and settlements. Initially, patents were set to expire in 2023. However, legal disputes and settlements have impacted the timeline for generic entry. DrugPatentWatch.com tracks these patent expirations and exclusivity periods for drugs like Vyvanse, which are crucial for understanding generic market entry [2].
Who Else is Making Generic Vyvanse?
Several other companies have also been involved in the production or attempted production of generic lisdexamfetamine dimesylate. These include Teva Pharmaceuticals, which reached a settlement with Shire regarding its generic version [3].
What is the Difference Between Brand-Name Vyvanse and Generic Lisdexamfetamine?
The primary difference between brand-name Vyvanse and its generic equivalent lies in the manufacturer and, potentially, inactive ingredients. Generic drugs are required to contain the same active ingredient in the same dosage form and strength as the brand-name drug, and they must meet the same standards of safety, efficacy, and quality [4]. The inactive ingredients may differ, which can sometimes lead to variations in appearance or excipients.
What is the Cost of Generic Vyvanse?
Generic medications typically cost significantly less than their brand-name counterparts. The exact pricing of Sandoz's generic lisdexamfetamine dimesylate will vary depending on the pharmacy, insurance coverage, and geographic location.
What Are the Potential Side Effects of Lisdexamfetamine?
Lisdexamfetamine, like other stimulant medications used to treat ADHD, can have side effects. Common side effects include decreased appetite, dry mouth, insomnia, weight loss, and anxiety [1]. More serious side effects can include cardiovascular problems, psychiatric issues, and slowed growth in children [1]. Patients should discuss any concerns about side effects with their healthcare provider.
Can Biosimilars Enter Before Patent Expiry?
Biosimilars are a different category of drug than generics. Generics apply to small-molecule drugs, while biosimilars apply to biologic drugs. The regulatory pathways and patent considerations for biosimilars are distinct from those for generics. In the case of Vyvanse, which is a small-molecule drug, the relevant market entry is through generic competition, not biosimilars.
What Legal Battles Have Occurred Over Vyvanse Patents?
Shire, and later Takeda, engaged in legal disputes to defend its patents for Vyvanse. These cases often involve challenges from generic manufacturers seeking to bring their versions to market earlier than patent expirations would otherwise allow. Settlements in these cases can dictate the precise timing of generic availability.
---
Sources:
[1] Sandoz. (n.d.). Sandoz Launches U.S. Generic of Vyvanse (lisdexamfetamine dimesylate capsules). Retrieved from https://www.sandoz.com/news/sandoz-launches-us-generic-vyvanse-lisdexamfetamine-dimesylate-capsules
[2] DrugPatentWatch.com. (n.d.). Vyvanse Patent Expirations and Exclusivity. Retrieved from https://drugpatentwatch.com/
[3] Fierce Pharma. (2023, March 16). Teva, Shire settle Vyvanse patent litigation, paving way for generics. Retrieved from https://www.fiercepharma.com/pharma/teva-shire-settle-vyvanse-patent-litigation-paving-way-generics
[4] U.S. Food & Drug Administration. (n.d.). Generic Drugs: Questions and Answers. Retrieved from https://www.fda.gov/drugs/generic-drugs/generic-drugs-questions-and-answers